Editorial review
Educational content is reviewed for source quality, clinical boundaries, and readability. It is not medical advice; confirm care decisions with a licensed clinician.
Telehealth ketamine for depression refers to ketamine treatment for major depressive disorder (MDD) or treatment-resistant depression (TRD) that is prescribed and monitored through virtual visits, often using take-home sublingual lozenges administered under remote supervision. It is the single most common reason patients seek out telehealth ketamine care, and it has the strongest clinical evidence base of any indication these platforms treat. This guide covers what the research shows, who is a reasonable candidate for the at-home model, what disqualifies a patient, and what to expect from evaluation through ongoing treatment.
Quick Answer
Telehealth ketamine for depression is a virtual-visit model in which a licensed prescriber evaluates a patient, prescribes sublingual ketamine lozenges, and monitors treatment remotely, typically for major depressive disorder or treatment-resistant depression. Candidates generally have moderate to moderately severe depression (PHQ-9 scores of 10-19), have tried at least one antidepressant without adequate relief, and have no acute suicidal crisis, uncontrolled cardiovascular disease, active psychosis, or active alcohol use disorder. Response rates in treatment-resistant depression run 50-70% in controlled studies, with effects often starting within 24-72 hours, though benefits typically fade within weeks to months without maintenance dosing.
The Evidence for Ketamine in Depression
Mechanism of Action
Ketamine's antidepressant mechanism differs from traditional antidepressants. SSRIs and SNRIs act on serotonin and norepinephrine systems over several weeks. Ketamine works on the glutamate system instead, acting as an NMDA receptor antagonist, a class of compound that blocks a specific glutamate receptor involved in synaptic signaling. According to StatPearls' clinical reference on ketamine pharmacology, this NMDA blockade triggers rapid synaptic changes and a surge in BDNF (brain-derived neurotrophic factor), a protein that supports neuroplasticity and the formation of new neural connections. The practical result is an antidepressant effect that can begin within hours of treatment, a speed that has no precedent among standard psychiatric medications. Additional pharmacological and chemical data on ketamine is available through the National Library of Medicine's PubChem database.
Clinical Evidence
Major depressive disorder (MDD) is a mood disorder marked by persistent low mood and loss of interest that interferes with daily functioning, as defined by the National Institute of Mental Health. According to the World Health Organizationdepression affects more than 280 million people worldwide and is a leading cause of disability globally.
Multiple randomized controlled trials have shown ketamine outperforms placebo for treatment-resistant depression (TRD), defined as depression that has not responded to at least two adequate antidepressant trials. Response rates in TRD populations range from 50% to 70% in controlled studies, and remission rates, while lower, are clinically meaningful at 25% to 35%. The antidepressant effect is typically time-limited without maintenance treatment. The FDA's approval of esketamine (Spravato) for treatment-resistant depression and major depressive disorder with suicidal ideation reflects the strength of this evidence base. For patients who have already failed multiple antidepressants, see our guide on next steps for treatment-resistant depression for a fuller breakdown of where ketamine fits among other options.
Who Qualifies for Telehealth Ketamine for Depression?
Psychiatric Criteria
Most telehealth ketamine platforms require a documented diagnosis of major depressive disorder or another depressive disorder, along with a history of at least one, and often two, antidepressant trials without adequate response. Platforms also screen for psychiatric stability: no acute suicidal crisis, no recent psychiatric hospitalization, and the ability to participate safely in an at-home treatment model without a clinician physically present.
Severity Considerations
Telehealth ketamine works best for patients with moderate to moderately severe depression. Patients with severe depression, particularly those with acute suicidal ideation or psychomotor retardation severe enough to impair self-care, are generally better served by in-person treatment with closer monitoring. Most platforms use the PHQ-9, a validated nine-item depression screening scale, at intake. Scores in the moderate range (10-19) are typically acceptable for the at-home model, while scores of 20 or higher may prompt a more intensive initial evaluation before treatment begins.
Compare your options
Move from the guide into a side-by-side comparison when you are ready to evaluate tradeoffs.
Compare optionsMedical Exclusions
Patients with certain medical conditions should not receive ketamine without special consideration from a prescriber. Drug interaction and precaution information is available through the National Library of Medicine's MedlinePlus consumer drug reference on ketamine.
Medical Conditions to Review Before Starting Ketamine
- Uncontrolled hypertension or significant cardiovascular disease
- Active liver disease, since ketamine is metabolized by the liver
- History of psychosis or schizophrenia
- Active alcohol use disorder, which can interact dangerously with ketamine and affect its metabolism
- Pregnancy
Response and Outcomes
What to Expect
Patients who respond to ketamine for depression often notice effects within 24 to 72 hours of the first treatment. Common reports include increased motivation and energy, an improved ability to feel positive emotions (what psychiatrists sometimes call "brightening of affect"), reduced rumination and negative thought spiraling, and improved sleep quality.
Not every patient responds. Non-response to an initial course does not necessarily mean ketamine will not work at all. Dose adjustment, a change in formulation, or transition to IV ketamine may produce a response in some patients who do not respond to sublingual protocols. Patients weighing whether to escalate to IV treatment should also review how sublingual and IV dosing compare, since dose equivalence between ketamine formulations is not one-to-one.
Key Takeaway
Ketamine's antidepressant effect is not permanent without continued treatment. Effects typically last weeks to months after an initial course, and patients who actively engage in psychotherapy and behavioral changes during the treatment window tend to sustain benefit longer.
Platforms That Treat Depression
Depression is the most common reason patients seek telehealth ketamine, and all major telehealth ketamine platforms list it as a primary indication. Because it is the highest-volume condition these platforms treat, intake processes, dosing protocols, and monitoring procedures for depression tend to be the most established compared with other indications. Maintenance schedules and pricing structures vary by platform. See our comparison of monthly subscription versus per-session pricing models for how ongoing depression treatment is typically billed.
What to Tell Your Provider
When pursuing telehealth ketamine for depression, come prepared to share the following with your prescriber.
What to Tell Your Provider
- Your formal diagnosis, if one has been given, and the date of onset
- The antidepressants you have tried, the doses, and why they were discontinued
- Your current depression severity; the PHQ-9 questionnaire will be used, but your own account matters too
- Whether you are currently in therapy, and your therapist's contact information if so
- Any history of mood cycling or hypomanic episodes, which matters for bipolar screening
If You Are Currently on Antidepressants
Many patients receive ketamine while continuing their existing antidepressants, and most antidepressants are compatible with ketamine treatment. Mood cycling or hypomanic episodes reported during intake can also prompt additional screening; if that history is present, review our guide on telehealth ketamine for bipolar depression for how that changes candidacy.
Important
MAO inhibitors (MAOIs) should not be combined with ketamine. They require a washout period before starting ketamine therapy. Discuss all current medications with your provider before beginning treatment.
Integrating Ketamine into a Depression Treatment Plan
Ketamine works best as part of a broader treatment approach, not as a standalone intervention. Patients who combine ketamine with active psychotherapy (particularly CBT, ACT, or psychodynamic therapy), regular physical activity, healthy sleep practices, reduced alcohol use, and social engagement tend to sustain their improvements longer and require less frequent maintenance dosing.
The neuroplastic window that ketamine opens is an opportunity, not a guarantee. The therapeutic work done during that window is what translates a temporary chemical change into a lasting change in mood and behavior. Patients should also know how to recognize and report side effects; see our guide on reporting adverse events during ketamine treatment for what to watch for and who to contact.
Learn More
Compare telehealth ketamine providers that treat depression and find one that matches your diagnosis and treatment history.
Frequently Asked Questions
Medicare coverage of ketamine therapy
Share
Related Reading
Have a question about this topic?
Use the contact page when you need to send feedback, request a correction, or ask about the resource.